<DOC>
	<DOCNO>NCT00918840</DOCNO>
	<brief_summary>PHPC-02 phase II , randomize , placebo-controlled trial design investigate whether therapeutic immunization highly active antiretroviral therapy ( HAART ) induce elevation HIV-specific T cell precursor high proliferative capacity ( PHPC ) HIV-1-infected individual , whether quantity PHPC correlate viral load set point follow analytical treatment interruption ( ATI ) . Subjects randomize receive either DermaVir Patch ( 8 subject per cohort ) DermaVir Patch Placebo ( 8 subject per cohort ) every four week three application receive maximally suppressive HAART . HAART discontinue Week 9 ATI period 20 week .</brief_summary>
	<brief_title>Antiretroviral-Sparing Concept With HIV-specific T Cell Precursors With High Proliferative Capacity ( PHPC )</brief_title>
	<detailed_description>16 subject maximally suppressive HAART randomize receive three dos either DermaVir Placebo immunotherapy . Subjects receive three DermaVir/Placebo treatment eight week ( Weeks 0 , 4 8 ) receive HAART . HAART discontinue 20 week ATI . Resumption HAART ATI subject experience : - A confirmed CD4+ cell decrease &gt; 50 % - A confirmed CD4+ cell decrease le 350 counts/mL - A confirmed VL increase &gt; 300,000 copy - Emergence CDC AIDS related event ( ) - Signs symptom clinically significant immunosuppression - The subject subject 's clinician wish restart HAART - The subject becomes pregnant</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Main inclusion Criteria : HIV1 infection On nonhydroxyurea base HAART least one year PreHAART CD4 nadir &gt; 250 cells/mm3 PreHAART viral load &gt; 5,000 copies/mL Undetectable viral load six month period precede study CD4 Tcell count &gt; 500 cells/mm3 six month period precede study Main exclusion Criteria : No skin disease No hypersensitivity adhesive tape Tegaderm No history keloid No history vitiligo , melasma , skin cancer No tattoo change pigment skin treatment sit No autoimmune diseases No hepatitis B , C coinfections</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immune Therapy</keyword>
	<keyword>DermaVir</keyword>
	<keyword>Treatment experience</keyword>
</DOC>